



FOR IMMEDIATE RELEASE

Compugen to Present at the Oppenheimer Annual Israeli Conference in Tel Aviv

Holon, Israel - May 16, 2016 – Compugen Ltd. ([NASDAQ: CGEN](http://www.nasdaq.com/quote/CGEN)), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer of Compugen, will present a corporate overview and update at the Oppenheimer 17th Annual Israeli Conference in Tel Aviv, Israel on Sunday, May 22, 2016.

About Compugen

Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The primary focus of the Company's current pipeline is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at <http://www.cgen.com>.

Company contact:

Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892